I. Durán

Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.

Y. Loriot, Pari Skamnioti, G. Banna, 2024, European urology focus.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

B. Escudier, S. Oosting, S. Bracarda, 2020 .

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma.

T. Powles, G. Sonpavde, Y. Loriot, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

T. Powles, G. Iyer, A. Necchi, 2024, Journal of Clinical Oncology.

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)

M. Méndez-Vidal, J. A. Arranz Arija, B. Pérez-Valderrama, 2024, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.